{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"TELA","limit":50},"count":50,"signals":[{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":100,"match_count":13,"context":"ur ability to commercialize or obtain regulatory approvals for our future products, or the effect of delays in commercializing or obtaining regulatory approvals; | | | | decreasing selling prices and pricing pressures; | | | | regulatory developments in the U.S., including regulatory developments due to current or future changes in the U.S. presidential administration and European markets; | | | | the potential i","filed_date":"2026-03-25","accession":"0001104659-26-034507","full_text":"https://origin.rootz.global/static/filing/0001104659-26-034507.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":100,"context":"g our business, additional risks that we do not know of or that we currently think are immaterial may also arise and materially affect our business. The realization of any of these risks could have a material adverse effect on our business, financial condition, results of operations, and our ability to accomplish our strategic objectives.* Risks Related to Achieving or Sustaining Profitability, Financial Position and Ca","filed_date":"2026-03-25","accession":"0001104659-26-034507","full_text":"https://origin.rootz.global/static/filing/0001104659-26-034507.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":37,"context":"curred in investigating or pursuing any Claim or any proceeding relating to any Claim. **Margin Stock** means margin stock within the meaning of Regulations U and X. **Material Adverse Change** and **Material Adverse Effect** means any event, occurrence, fact, development or circumstance that has had, or could reasonably be expected to have, a material adverse change in or a material adverse effect upon (i) the business","filed_date":"2025-11-14","accession":"0001104659-25-112653","full_text":"https://origin.rootz.global/static/filing/0001104659-25-112653.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":57,"context":"o ratify the appointment of KPMG LLP, or KPMG, as our independent registered public accounting firm for the 2025 fiscal year;  3. To approve, on a non-binding, advisory basis, the compensation of our named executive officers;  4. To approve, on a non-binding, advisory basis, the preferred frequency of future advisory votes on the compensation of our named executive officers;  5. To approve an amendment to the Amended an","filed_date":"2025-04-17","accession":"0001104659-25-036020","full_text":"https://origin.rootz.global/static/filing/0001104659-25-036020.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":100,"match_count":14,"context":"igher charge for excess and obsolete inventory. Amortization of Intangible Assets Amortization of intangible assets was $0.4 million for both the years ended December 31, 2024 and 2023.  Gross Margin Gross margin decreased to 67% for the year ended December 31, 2024 from 69% for the year ended December31, 2023. The decrease was primarily due to higher expense recognized for excess and obsolete inventory adjustments as","filed_date":"2025-03-21","accession":"0001558370-25-003460","full_text":"https://origin.rootz.global/static/filing/0001558370-25-003460.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":94,"context":"g our business, additional risks that we do not know of or that we currently think are immaterial may also arise and materially affect our business. The realization of any of these risks could have a material adverse effect on our business, financial condition, results of operations, and our ability to accomplish our strategic objectives.* Risks Related to Achieving or Sustaining Profitability, Financial Position and Ca","filed_date":"2025-03-21","accession":"0001558370-25-003460","full_text":"https://origin.rootz.global/static/filing/0001558370-25-003460.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":35,"context":"ting of Stockholdersand2024 Proxy Statement [TABLE OF CONTENTS](#TOC) |  |  EXECUTIVE COMPENSATION |  |  | This section discusses the material components of the executive compensation program for our named executive officers. In 2023, our named executive officers were Antony Koblish, our President and Chief Executive Officer, Roberto Cuca, our Chief Operating Officer and Chief Financial Officer, and Paul Talmo, our Chie","filed_date":"2024-04-18","accession":"0001104659-24-048835","full_text":"https://origin.rootz.global/static/filing/0001104659-24-048835.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":100,"match_count":13,"context":"ur ability to commercialize or obtain regulatory approvals for our future products, or the effect of delays in commercializing or obtaining regulatory approvals; | | | | decreasing selling prices and pricing pressures; | | | | regulatory developments in the U.S. and European markets; | | | | the potential impact of healthcare reform in the U.S., including the Inflation Reduction Act of 2022, and measures being ta","filed_date":"2024-03-22","accession":"0001558370-24-003782","full_text":"https://origin.rootz.global/static/filing/0001558370-24-003782.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":78,"context":"g our business, additional risks that we do not know of or that we currently think are immaterial may also arise and materially affect our business. The realization of any of these risks could have a material adverse effect on our business, financial condition, results of operations, and our ability to accomplish our strategic objectives.* Risks Related to Achieving or Sustaining Profitability, Financial Position and Ca","filed_date":"2024-03-22","accession":"0001558370-24-003782","full_text":"https://origin.rootz.global/static/filing/0001558370-24-003782.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":33,"context":"ting of Stockholdersand2023 Proxy Statement [TABLE OF CONTENTS](#TOC) |  |  EXECUTIVE COMPENSATION |  |  | This section discusses the material components of the executive compensation program for our named executive officers. In 2022, our named executive officers were Antony Koblish, our President and Chief Executive Officer, Roberto Cuca, our Chief Operating Officer and Chief Financial Officer, and Paul Talmo, our Chie","filed_date":"2023-04-17","accession":"0001104659-23-046172","full_text":"https://origin.rootz.global/static/filing/0001104659-23-046172.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":100,"match_count":15,"context":"ability to commercialize or obtain regulatory approvals for our future products, or the effect of delays in commercializing or obtaining regulatory approvals; | | | | | decreasing selling prices and pricing pressures; | | | | | regulatory developments in the U.S. and European markets; | | | | | the potential impact of healthcare reform in the United States, including the Inflation Reduction Act of 2022, and meas","filed_date":"2023-03-23","accession":"0001558370-23-004468","full_text":"https://origin.rootz.global/static/filing/0001558370-23-004468.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":42,"context":"g our business, additional risks that we do not know of or that we currently think are immaterial may also arise and materially affect our business. The realization of any of these risks could have a material adverse effect on our business, financial condition, results of operations, and our ability to accomplish our strategic objectives.* Risks Related to Achieving or Sustaining Profitability, Financial Position and Ca","filed_date":"2023-03-23","accession":"0001558370-23-004468","full_text":"https://origin.rootz.global/static/filing/0001558370-23-004468.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":37,"context":"nvolves a minor violation that would not be subject to legal action by the FDA or which involves no violation, e.g., normal stock rotation practices, routine equipment adjustments and repairs, etc. **Material Adverse Effect** means with respect to any event, act, condition or occurrence of whatever nature (including any adverse determination in any litigation, arbitration, or governmental investigation or proceeding), w","filed_date":"2022-05-31","accession":"0001104659-22-066225","full_text":"https://origin.rootz.global/static/filing/0001104659-22-066225.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":26,"context":"g of Stockholdersand2022 Proxy Statement|21 [TABLE OF CONTENTS](#TOC) |  |  EXECUTIVE COMPENSATION |  |  | This section discusses the material components of the executive compensation program for our named executive officers. In 2021, our named executive officers were Antony Koblish, our President and Chief Executive Officer, E.Skott Greenhalgh, Ph.D., our Chief Technology Officer, and Peter Murphy, our Chief Commercial","filed_date":"2022-04-21","accession":"0001104659-22-048036","full_text":"https://origin.rootz.global/static/filing/0001104659-22-048036.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":43,"context":"s Related to COVID-19** | | | The ongoing COVID-19 pandemic is negatively impacting certain aspects of our business and, depending on the severity and duration beyond current experience, could have a material adverse effect on our business, results of operations and financial condition. | | **Risks Related to Achieving or Sustaining Profitability, Financial Position and Capital Requirements** | | | We have incurred sign","filed_date":"2022-03-23","accession":"0001558370-22-004151","full_text":"https://origin.rootz.global/static/filing/0001558370-22-004151.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":24,"context":"ting of Stockholdersand2021 Proxy Statement [TABLE OF CONTENTS](#TOC) |  |  EXECUTIVE COMPENSATION |  |  | This section discusses the material components of the executive compensation program for our named executive officers. In 2020, our named executive officers were Antony Koblish, our President and Chief Executive Officer, Maarten Persenaire, M.D., our Chief Medical Officer, and E. Skott Greenhalgh, Ph.D., our Chief","filed_date":"2021-04-22","accession":"0001104659-21-053405","full_text":"https://origin.rootz.global/static/filing/0001104659-21-053405.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":42,"context":"* **Risks Related to COVID-19** | | | The COVID-19 pandemic is negatively impacting certain aspects of our business and, depending on the severity and duration beyond current experience, could have a material adverse effect on our business, results of operations and financial condition. | | **Risks Related to Achieving or Sustaining Profitability, Financial Position and Capital Requirements** | | | We have incurred sign","filed_date":"2021-03-25","accession":"0001558370-21-003483","full_text":"https://origin.rootz.global/static/filing/0001558370-21-003483.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":29,"context":"he underwriters option to purchase additional shares. We received net proceeds of $50.6million after deducting underwriting discounts, commissions and other offering expenses.  On January29, 2020, we appointed Peter Murphy as our Chief Commercial Officer. Mr.Murphy is responsible for our continued strategic expansion of our commercial operations.  On April 20, 2020, Lisa Colleran and Doug Evans were appointed as ClassI directors of","filed_date":"2020-04-23","accession":"0001104659-20-050364","full_text":"https://origin.rootz.global/static/filing/0001104659-20-050364.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":41,"context":"ffect, if any, any future healthcare reform legislation or policies will have on our business,  32 [Table of Contents](#TOC) current and future healthcare reform legislation and policies could have a material adverse effect on our business and financial condition. Pricing and Reimbursement In the U.S. and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will","filed_date":"2020-03-30","accession":"0001558370-20-003346","full_text":"https://origin.rootz.global/static/filing/0001558370-20-003346.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":98,"match_count":11,"context":"dness, (v) judgments, (vi) change of control, (vii) bankruptcy and insolvency, (viii) impairment of security, (ix) key permit events, (x) termination of a pension plan, (xi) regulatory matters, (xii) material adverse effect and (xiii) breach of material contracts.  13 [Table of Contents](#TOC) TELA Bio,Inc. **Notes to Unaudited Interim Consolidated Financial Statements (Continued)** In addition, the Company must maintai","filed_date":"2024-08-13","accession":"0001558370-24-012060","full_text":"https://origin.rootz.global/static/filing/0001558370-24-012060.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":90,"match_count":10,"context":"dness, (v) judgments, (vi) change of control, (vii) bankruptcy and insolvency, (viii) impairment of security, (ix) key permit events, (x) termination of a pension plan, (xi) regulatory matters, (xii) material adverse effect and (xiii) breach of material contracts.  In addition, the Company must maintain minimum net revenue levels tested quarterly. In the event of default under the MidCap Credit Agreement, the Company wo","filed_date":"2025-08-11","accession":"0001558370-25-011052","full_text":"https://origin.rootz.global/static/filing/0001558370-25-011052.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":90,"match_count":10,"context":"dness, (v) judgments, (vi) change of control, (vii) bankruptcy and insolvency, (viii) impairment of security, (ix) key permit events, (x) termination of a pension plan, (xi) regulatory matters, (xii) material adverse effect and (xiii) breach of material contracts.  13 [Table of Contents](#TOC) TELA Bio,Inc. **Notes to Unaudited Interim Consolidated Financial Statements (Continued)** In addition, the Company must maintai","filed_date":"2024-11-08","accession":"0001558370-24-015050","full_text":"https://origin.rootz.global/static/filing/0001558370-24-015050.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":82,"match_count":9,"context":"dness, (v) judgments, (vi) change of control, (vii) bankruptcy and insolvency, (viii) impairment of security, (ix) key permit events, (x) termination of a pension plan, (xi) regulatory matters, (xii) material adverse effect and (xiii) breach of material contracts.  In addition, the Company must maintain minimum net revenue levels tested quarterly. In the event of default under the MidCap Credit Agreement, the Company wo","filed_date":"2025-05-08","accession":"0001558370-25-006994","full_text":"https://origin.rootz.global/static/filing/0001558370-25-006994.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"quity Awards(1) |  |  |  |  |  |  | |  |  |  Initial Equity Award |  |  |  The Initial Equity Award consists of: (1)an option to purchase 8,040 shares of common stock vesting in 36 equal monthly installments on the monthly anniversary of the date of grant; and (2)a restricted stock unit award with respect to 4,702 shares of common stock vesting in three equal annual installments on the first three an","filed_date":"2024-04-18","accession":"0001104659-24-048835","full_text":"https://origin.rootz.global/static/filing/0001104659-24-048835.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"Equity Awards |  |  |  |  |  |  | |  |  |  Initial Equity Award |  |  |  The Initial Equity Award consists of: (1)an option to purchase 8,040 shares of common stock vesting in 36 equal monthly installments on the monthly anniversary of the date of grant; and (2)a restricted stock unit award with respect to 4,702 shares of common stock vesting in three equal annual installments on the first three an","filed_date":"2022-04-21","accession":"0001104659-22-048036","full_text":"https://origin.rootz.global/static/filing/0001104659-22-048036.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"Equity Awards |  |  |  |  |  |  | |  |  |  Initial Equity Award |  |  |  The Initial Equity Award consists of: (1)an option to purchase 9,300 shares of common stock vesting in 36 equal monthly installments on the monthly anniversary of the date of grant; and (2)a restricted stock unit award with respect to 6,375 shares of common stock vesting in three equal annual installments on the first three an","filed_date":"2025-04-17","accession":"0001104659-25-036020","full_text":"https://origin.rootz.global/static/filing/0001104659-25-036020.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"Equity Awards |  |  |  |  |  |  | |  |  |  Initial Equity Award |  |  |  The Initial Equity Award consists of: (1)an option to purchase 8,040 shares of common stock vesting in 36 equal monthly installments on the monthly anniversary of the date of grant; and (2)a restricted stock unit award with respect to 4,702 shares of common stock vesting in three equal annual installments on the first three an","filed_date":"2023-04-17","accession":"0001104659-23-046172","full_text":"https://origin.rootz.global/static/filing/0001104659-23-046172.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"es of our common stock, in each case, at a per-share exercise price equal to the initial public offering price of our common stock. Each such stock option is eligible to vest in 36 equal monthly installments on each monthly anniversary of the grant date, subject to the non-employee directors continued service through the applicable vesting date.  DIRECTOR COMPENSATION TABLE  The following table below","filed_date":"2020-04-23","accession":"0001104659-20-050364","full_text":"https://origin.rootz.global/static/filing/0001104659-20-050364.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":58,"match_count":1,"context":"ill remain prion disease-free or that a future outbreak or presence of other unintended and potentially hazardous agents would not adversely affect our products or patients that may receive them. The geographic concentration of our supply chain increases our vulnerability to disruption due to natural disasters, disease or other events. If there is a disruption in the supply of ovine rumen to our manufacturer and supplier","filed_date":"2026-03-25","accession":"0001104659-26-034507","full_text":"https://origin.rootz.global/static/filing/0001104659-26-034507.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":56,"match_count":7,"context":"her charge for excess and obsolete inventory. Amortization of Intangible Assets Amortization of intangible assets was $95,000 for both the three months ended September 30, 2024 and 2023. Gross Margin Gross margin decreased to 68% for the three months ended September 30, 2024 from 69% for the three months ended September 30, 2023. The decrease was primarily due to a higher charge for excess and obsolete inventory as a p","filed_date":"2024-11-08","accession":"0001558370-24-015050","full_text":"https://origin.rootz.global/static/filing/0001558370-24-015050.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":56,"match_count":7,"context":"vidual (a) is not and will not become a party to (1) any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the Corporation, will act or vote on any issue or question (a Voting Commitment) that has not been disclosed to the Corporation and (2) any Voting Commitment that could limit or interfere with suc","filed_date":"2019-11-19","accession":"0001104659-19-065432","full_text":"https://origin.rootz.global/static/filing/0001104659-19-065432.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":56,"match_count":7,"context":"vidual (a) is not and will not become a party to (1) any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the Corporation, will act or vote on any issue or question (a Voting Commitment) that has not been disclosed to the Corporation and (2) any Voting Commitment that could limit or interfere with suc","filed_date":"2019-11-05","accession":"0001047469-19-006067","full_text":"https://origin.rootz.global/static/filing/0001047469-19-006067.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":50,"match_count":5,"context":"dness, (v) judgments, (vi) change of control, (vii) bankruptcy and insolvency, (viii) impairment of security, (ix) key permit events, (x) termination of a pension plan, (xi) regulatory matters, (xii) material adverse effect and (xiii) breach of material contracts.  In addition, the Company must maintain minimum net revenue levels tested quarterly. In the event of default under the MidCap Credit Agreement, the Company wo","filed_date":"2025-11-14","accession":"0001104659-25-112476","full_text":"https://origin.rootz.global/static/filing/0001104659-25-112476.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":48,"match_count":1,"context":"or that a future outbreak or presence of other unintended and potentially hazardous agents  50 [Table of Contents](#TOC) would not adversely affect our products or patients that may receive them. The geographic concentration of our supply chain increases our vulnerability to disruption due to natural disasters, disease or other events. If there is a disruption in the supply of ovine rumen to our manufacturer and supplier","filed_date":"2025-03-21","accession":"0001558370-25-003460","full_text":"https://origin.rootz.global/static/filing/0001558370-25-003460.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":48,"match_count":6,"context":"a higher charge for excess and obsolete inventory. Amortization of Intangible Assets Amortization of intangible assets was $95,000 for both the three months ended June 30, 2024 and 2023. Gross Margin Gross margin decreased to 69% for the three months ended June 30, 2024 from 70% for the three months ended June 30, 2023. The decrease was primarily due to a higher charge for excess and obsolete inventory as a percentage","filed_date":"2024-08-13","accession":"0001558370-24-012060","full_text":"https://origin.rootz.global/static/filing/0001558370-24-012060.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":48,"match_count":6,"context":".5 million to $76.5 million, representing 27% to 31% year-over-year growth. | | TELA delivered double-digit growth in the second quarter notwithstanding some market disruptions from customer-targeted cyberattacks that we believe led to a shortfall in procedures at some of our largest or most rapidly growing contracted accounts, said Antony Koblish, President and CEO of TELA Bio. We believe many of thes","filed_date":"2024-08-12","accession":"0001104659-24-088353","full_text":"https://origin.rootz.global/static/filing/0001104659-24-088353.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"totaling $324,188, $180,500 and $166,251, respectively, of which 75% was paid in cash, and 25% was paid in restricted stockunits. Each of the restricted stockunits will vest in four equal annual installments beginning on March31, 2022. Such amounts represented approximately 62% of Mr.Koblishs annual base salary for the year ended December31, 2020 and 48% of each of Drs. Persenaires and Greenhalghs an","filed_date":"2021-04-22","accession":"0001104659-21-053405","full_text":"https://origin.rootz.global/static/filing/0001104659-21-053405.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":40,"match_count":5,"context":"ducts, they will remain subject to extensive regulatory scrutiny. | | | | If guidelines for soft-tissue reconstruction surgery change or the standard of care evolves, we may need to redesign and seek new marketing authorization from the U.S. Food and Drug Administration for our OviTex and OviTex PRS products or other products we may commercialize in the future. | | Risks Related to Our Business and Products","filed_date":"2026-03-25","accession":"0001104659-26-034507","full_text":"https://origin.rootz.global/static/filing/0001104659-26-034507.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":40,"match_count":5,"context":"ur ability to commercialize or obtain regulatory approvals for our future products, or the effect of delays in commercializing or obtaining regulatory approvals; | | | | decreasing selling prices and pricing pressures; | | | | regulatory developments in the U.S., including regulatory developments due to changes in the U.S. presidential administration and European markets; | | | | the potential impact of healthcar","filed_date":"2025-11-14","accession":"0001104659-25-112476","full_text":"https://origin.rootz.global/static/filing/0001104659-25-112476.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":40,"match_count":5,"context":"ur ability to commercialize or obtain regulatory approvals for our future products, or the effect of delays in commercializing or obtaining regulatory approvals; | | | | decreasing selling prices and pricing pressures; | | | | regulatory developments in the U.S., including regulatory developments due to changes in the U.S. presidential administration and European markets; | | | | the potential impact of healthcar","filed_date":"2025-08-11","accession":"0001558370-25-011052","full_text":"https://origin.rootz.global/static/filing/0001558370-25-011052.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":40,"match_count":5,"context":"ur ability to commercialize or obtain regulatory approvals for our future products, or the effect of delays in commercializing or obtaining regulatory approvals; | | | | decreasing selling prices and pricing pressures; | | | | regulatory developments in the U.S., including regulatory developments due to changes in the U.S. presidential administration and European markets; | | | | the potential impact of healthcar","filed_date":"2025-05-08","accession":"0001558370-25-006994","full_text":"https://origin.rootz.global/static/filing/0001558370-25-006994.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":40,"match_count":5,"context":"ducts, they will remain subject to extensive regulatory scrutiny. | | | | If guidelines for soft-tissue reconstruction surgery change or the standard of care evolves, we may need to redesign and seek new marketing authorization from the U.S. Food and Drug Administration for our OviTex and OviTex PRS products or other products we may commercialize in the future. | | Risks Related to Our Business and Products","filed_date":"2025-03-21","accession":"0001558370-25-003460","full_text":"https://origin.rootz.global/static/filing/0001558370-25-003460.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":40,"match_count":5,"context":"ur ability to commercialize or obtain regulatory approvals for our future products, or the effect of delays in commercializing or obtaining regulatory approvals; | | | | decreasing selling prices and pricing pressures; | | | | regulatory developments in the U.S. and European markets; | | | | the potential impact of healthcare reform in the U.S., including the Inflation Reduction Act of 2022, and measures being ta","filed_date":"2024-05-10","accession":"0001558370-24-007784","full_text":"https://origin.rootz.global/static/filing/0001558370-24-007784.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":40,"match_count":5,"context":"ducts, they will remain subject to extensive regulatory scrutiny. | | | | If guidelines for soft-tissue reconstruction surgery change or the standard of care evolves, we may need to redesign and seek new marketing authorization from the U.S. Food and Drug Administration for our OviTex and OviTex PRS products or other products we may commercialize in the future. | | Risks Related to Our Business and Products","filed_date":"2024-03-22","accession":"0001558370-24-003782","full_text":"https://origin.rootz.global/static/filing/0001558370-24-003782.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":40,"match_count":5,"context":"ability to commercialize or obtain regulatory approvals for our future products, or the effect of delays in commercializing or obtaining regulatory approvals; | | | | | decreasing selling prices and pricing pressures; | | | | | regulatory developments in the U.S. and European markets; | | 2 [Table of Contents](#TOC) | | | the potential impact of healthcare reform in the U.S., including the Inflation Reduction Ac","filed_date":"2023-11-13","accession":"0001558370-23-018822","full_text":"https://origin.rootz.global/static/filing/0001558370-23-018822.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":40,"match_count":5,"context":"ability to commercialize or obtain regulatory approvals for our future products, or the effect of delays in commercializing or obtaining regulatory approvals; | | | | | decreasing selling prices and pricing pressures; | | | | | regulatory developments in the U.S. and European markets; | | | | | the potential impact of healthcare reform in the U.S., including the Inflation Reduction Act of 2022, and measures bein","filed_date":"2023-08-10","accession":"0001558370-23-014494","full_text":"https://origin.rootz.global/static/filing/0001558370-23-014494.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":40,"match_count":5,"context":"ability to commercialize or obtain regulatory approvals for our future products, or the effect of delays in commercializing or obtaining regulatory approvals; | | | | | decreasing selling prices and pricing pressures; | | | | | regulatory developments in the U.S. and European markets; | | | | | the potential impact of healthcare reform in the U.S., including the Inflation Reduction Act of 2022, and measures bein","filed_date":"2023-05-11","accession":"0001558370-23-009426","full_text":"https://origin.rootz.global/static/filing/0001558370-23-009426.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":40,"match_count":5,"context":"cts, they will remain subject to extensive regulatory scrutiny. | | | | | If guidelines for soft-tissue reconstruction surgery change or the standard of care evolves, we may need to redesign and seek new marketing authorization from the U.S. Food and Drug Administration (FDA) for our OviTex and OviTex PRS products or other products we may commercialize in the future. | | Risks Related to Our Business and Pr","filed_date":"2023-03-23","accession":"0001558370-23-004468","full_text":"https://origin.rootz.global/static/filing/0001558370-23-004468.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":40,"match_count":5,"context":"cts, they will remain subject to extensive regulatory scrutiny. | | | | | If guidelines for soft-tissue reconstruction surgery change or the standard of care evolves, we may need to redesign and seek new marketing authorization from the FDA for our OviTex and OviTex PRS products or other products we may commercialize in the future. | | | | | Healthcare policy changes, including recently enacted legislation","filed_date":"2022-03-23","accession":"0001558370-22-004151","full_text":"https://origin.rootz.global/static/filing/0001558370-22-004151.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TELA","company":"TELA Bio, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":40,"match_count":5,"context":"cts, they will remain subject to extensive regulatory scrutiny. | | | | | If guidelines for soft tissue reconstruction surgery change or the standard of care evolves, we may need to redesign and seek new marketing authorization from the FDA for our OviTex and OviTex PRS products or other products we may commercialize in the future. | | | | | Healthcare policy changes, including recently enacted legislation","filed_date":"2021-03-25","accession":"0001558370-21-003483","full_text":"https://origin.rootz.global/static/filing/0001558370-21-003483.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"90d0fef9ad71905345747c54db0858496fbf674f7f450ba4d454b88271cd11f6","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"082fe68c7fb59c2e26135f2adac1f3c243a83bb5266b371ec0931c1a806d0dc8","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":82,"hourly_limit":500,"remaining":418,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}